KITHER BIOTECH - Key Persons

Job Titles:

• Associate Professor
• Scientific Co - Founder

Alessandra Ghigo is Associate Professor in the Department of Biotechnology in the University of Torino. She has worked on PI3K scaffold function for more than a decade and provided seminal contributions to the understanding of the non-catalytic role of PI3Kgamma in the control of cAMP regulation. She is author of more than 90 publications in highly reputed journals, including Science, Science Translational Medicine and Circulation. She is an internationally recognized as expert in cAMP regulation, invited speaker in prestigious conferences including the Gordon Conference on Cyclic Nucleotides. She designed KIT2014 and found its action in Cystic Fibrosis. As such she has been regularly invited speaker at the European and at the North American Cystic Fibrosis meetings.

Job Titles:

• Head of Medical Affairs ( CMO )

Carla Uslenghi has over 25 years of experience in the pharmaceutical industry spending the majority of her working life in Medical Affairs (including leading and developing the medical strategy and activitites, medical oversight to the clinical trials program execution, medical support and input to product marketing strategy, product specific medical training) in different therapeutical areas in multinational companies. She has developed experience also at Regulatory Affairs level managing an international regulatory project.

Job Titles:

• Executive Director
• Member of the Executive Board

Dimitrios Goundis is an Executive Board Member at Kither Biotech and brings over 30 years of experience in the life science and biotech sector, in senior management roles, and participated in 2 IPOs (NASDAQ in 2000 and SWX in 2005) and a number of financial and business transactions.

Job Titles:

• Professor of Experimental Biology
• Scientific Co - Founder

Emilio Hirsch is Professor of Experimental Biology in the Medical School, University of Torino since 2005. He has authored more than 200 scientific publications that received more than 18000 citations. He is an internationally recognized scientist, elected member of the European Molecular Biology Organization (EMBO), Fellow of the International Society of Heart Research (ISHR) and receiver of the American Association for Cancer Research (AACR) innovator prize. He contributed seminal work in the characterization of key signal transduction enzymes named PI3Ks with publications in Science, Nature and Cell. He was involved in the identification of the first PI3K inhibitors for the treatment of cancer and inflammation. His experience in drug discovery was seminal to the design of Kither's KITCL27. He discovered the scaffolding function of PI3Kgamma that led to the design of Kither's KIT2014.

Job Titles:

• Engineer
• Non - Executive Director

Heikki Lanckriet is a biochemical engineer with a passion for combining the worlds of scientific innovation and business. After having founded his own company 19 years ago, he has focussed on building, growing and investing in innovative life science companies. He is currently the CEO of, and a significant shareholder in, 4basebio, an AIM listed company focussing on next generation gene therapies. Prior to this, Heikki led Expedeon, a German listed life sciences company. In 2020 Heikki concluded the sale to Abcam plc for 120m of Expedeon's proteomics and immunology business; and the subsequent rebranding and refocus of the company to 2Invest AG, an investment company with a focus on the life science sector. Heikki continues to be heavily involved in the science also acting as CSO for 4basebio and Expedeon previously. He holds a Bachelor's and Master's degree in Biochemical Engineering from the University of Ghent, Belgium and a PhD in Chemical Engineering from the University of Cambridge, UK. He has also published papers in high impact peer-reviewed international scientific journals and is named inventor on a multitude of patents

Job Titles:

• Chairman of the Board

Laura is a manager and entrepreneur in the healthcare sector with strong academic background both in medical science and in business (MBA at Bocconi University, Milan). In 2015 Laura was named among the 10 most innovative women managers in Italy by Wired and in 2006 she has been highlighted among the 10 ‘Women to watch' by the Wall Street Journal Europe. After a period as psychiatrist in public structures (1978-1990), Laura joined the family pharmaceutical Company Crinos (then Sirton) holding a series of managerial offices. Leveraging on the experience of the family Company, she founded the biotech Gentium which then she listed in the USA at Nasdaq and sold to Jazz Pharmaceuticals (2014). She is from 2016 a member of the Board of Directors of the listed biotech company MolMed Spa. Laura is also Chairman of Bio4Dreams, the first incubator in the field of life sciences in Italy, and Vice-Chairman of IAG, the largest business angels network in the Country. Laura sits on the Board of Directors of start-ups operating in the field of neuromodulation such as Newronika and Wise and has been a Member of the Shareholdership Commission of IIT (Istituto Italiano di Tecnologia). She is a Board Member of Credem Private Equity Sgr. She was President of Pio Albergo Trivulzio (2011-2014), one of the main geriatric care facilities in Italy and Europe. She was also an Independent Director of Sorin Group (2012-2014), a multinational leader in the field of medical devices for the treatment of cardiovascular diseases which then merged with USA Company Cyberonics creating LivaNova.

Job Titles:

• Executive Director
• Business and Investment Executive

Marco Kevin Malisani is a business and investment executive, with experience as investor and manager of start-up companies in Italy and the UK. He has significant experience in equity investment and business management in Europe and South East Asia.

Job Titles:

• Biomedical Engineer
• Non - Executive Director

Pietro is a biomedical engineer with over a decade of experience in life sciences investments and

Job Titles:

• Founder

Dr. Blasi is Founder and a Member of the Executive Committee of the European Registry of Bronchiectasis (EMBARC), the Italian Bronchiectasis Registry (IRIDE), and the Italian NTM Registry (IRENE), as well as a Fellow and Honorary Member of the European Respiratory Society, and a Member of Istituto Lombardo Accademia di Science e Lettere. He serves on the Editorial Board for several journals focused on his areas of expertise, including Pulmonary Pharmacology and Therapeutics, Respiratory Research, Respiratory Medicine, COPD, and Biomedicines

Isabelle Fajac is a Pulmonologist, Professor of Physiology at APHP.Centre - Université de Paris, Paris, France. She has completed a PhD on cystic fibrosis gene transfer at INSERM. She works at the Cochin Hospital cystic fibrosis centre which cares for 500 adult patients with cystic fibrosis and is the largest adult cystic fibrosis centre in France. She has a long-standing interest in clinical biomarkers of CFTR function and she has been Principal Investigator of several academic and pharmaceutical clinical trials on cystic fibrosis. She has been Chair of the European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN) and an Associate-Editor of the Journal of Cystic Fibrosis. She is the President of the European Cystic Fibrosis Society. Kither Biotech is a biopharmaceutical company developing signal transduction modulators for the treatment of rare respiratory diseases.

Job Titles:

• Doctor
• Head of Scientific Affairs

Valentina Sala is Doctor in Molecular Biotechnology with a PhD in Molecular Medicine at the University of Turin (Italy). Valentina has 15+ years of experience in biomedical research in the cardiovascular and pulmonary fields. She is author of more than 25 publications on peer reviewed international journals. She has collaborated with Kither Biotech since 2016 and, after a PostDoc in the laboratory of Prof. Alessandra Ghigo, she joined the team as Drug Development Specialist.